Assimon Magdalene M, Mousa Shaker, Shaker Olfat, Pai Amy Barton
Albany College of Pharmacy and Health Sciences, Albany, New York 12208, USA.
Consult Pharm. 2010 Jan;25(1):41-54. doi: 10.4140/TCP.n.2010.41.
To review phosphate-binder choice and mortality in hemodialysis patients.
A literature search was performed using the PUBMED database to identify clinical trials published from January 1966 through January 2009. Search terms included: sevelamer and mortality, calcium acetate and mortality, and calcium carbonate and mortality.
Clinical trials relating the effect of phosphate-binder choice on cardiovascular disease and mortality in hemodialysis patients, judged to be pertinent by the authors, were selected for discussion. DATA SYNTHESIS/CONCLUSIONS: The Renagel in New Dialysis (RIND) extension study and the Dialysis Clinical Outcomes Revisted (DCOR) study were the first clinical trials to compare the effects of calcium-based phosphate binders and sevelamer hydrochloride on mortality in hemodialysis patients. Based on the results of these and other studies evaluated, it is still unclear if sevelamer hydrochloride has a survival benefit in hemodialysis patients over calcium-based phosphate binders.
回顾血液透析患者中磷结合剂的选择与死亡率。
使用PUBMED数据库进行文献检索，以识别1966年1月至2009年1月发表的临床试验。检索词包括：司维拉姆与死亡率、醋酸钙与死亡率、碳酸钙与死亡率。
作者认为与磷结合剂选择对血液透析患者心血管疾病和死亡率的影响相关的临床试验被选作讨论对象。数据综合/结论：新型透析中使用Renagel（RIND）扩展研究和透析临床结局再评估（DCOR）研究是首批比较钙基磷结合剂和盐酸司维拉姆对血液透析患者死亡率影响的临床试验。基于这些及其他评估研究的结果，目前仍不清楚盐酸司维拉姆在血液透析患者中是否比钙基磷结合剂具有生存获益。
